Zacks.com on MSN4d
AstraZeneca Rises Almost 9% in a Month: How to Play the Stock
AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
AstraZeneca Post 2024 Earnings: Unwanted Headwinds Warrant Downgrade To Hold
AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...
BioSpace5d
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
BioWorld3d
Meiragtx filing MAA on visual benefits with gene therapy
A paper published in The Lancet showed that four out of four young children with Leber congenital amaurosis 4 retinal dystrophy due to a genetic deficiency of Aryl-hydrocarbon-interacting protein-like ...